Opiant Pharmaceuticals, Inc. Common Stock
OPNT
OPNT was delisted on the 1st of March, 2023.
31 hedge funds and large institutions have $9.7M invested in Opiant Pharmaceuticals, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 9 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
34% more capital invested
Capital invested by funds: $7.26M → $9.7M (+$2.44M)
7% more funds holding
Funds holding: 29 → 31 (+2)
33% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Apis Capital Advisors
New York
|
+$183K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$161K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$147K |
| 4 |
NFSG
Newbridge Financial Services Group
Boca Raton,
Florida
|
+$37.6K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$25.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
-$221K |
| 2 |
Renaissance Technologies
New York
|
-$160K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$24.2K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$17.4K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$16K |
OPNT Hedge Fund Activity: Q1 2021 in Review
31 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Opiant Pharmaceuticals, Inc. Common Stock (OPNT) for Q1 2021, worth a combined $9.7M — up 34% from $7.26M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new OPNT positions and 3 closed out — a net gain of 2 holders — while 6 added to existing stakes and 9 trimmed.
The largest buyer was Apis Capital Advisors, adding an estimated $183K. The largest seller was Northern Trust, cutting an estimated $221K.
- 31 institutional investors held Opiant Pharmaceuticals, Inc. Common Stock (OPNT) as of Q1 2021, up from 29 in Q4 2020.
- Funds reported $9.7M of Opiant Pharmaceuticals, Inc. Common Stock stock for Q1 2021, up 34% quarter-over-quarter.
- 5 funds opened new Opiant Pharmaceuticals, Inc. Common Stock positions in Q1 2021 and 3 closed out, a net change of +2 holders.
- The largest Opiant Pharmaceuticals, Inc. Common Stock buyer in Q1 2021 was Apis Capital Advisors, an estimated $183K added.
- The largest Opiant Pharmaceuticals, Inc. Common Stock seller in Q1 2021 was Northern Trust, an estimated $221K sold.
Based on aggregated 13F filings for Q1 2021.